Even as Johnson & Johnson’s oncology superstar Darzalex Faspro racks up megablockbuster sales and reshapes the multiple ...
The FDA approved a new DARZALEX FASPRO combination therapy for newly diagnosed multiple myeloma patients who are not eligible ...
The FDA approved Darzalex Faspro with Velcade, Revlimid and dexamethasone for newly diagnosed multiple myeloma ineligible for ...
Darzalex Faspro, in combination with an anti-cancer triplet, is the first anti-CD38-based regimen for newly diagnosed ...
D-VRd is the only quadruplet regimen approved for patients with newly diagnosed multiple myeloma, irrespective of transplant ...
Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration (FDA) approved DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide and ...
Multiple Myeloma (MM) research is at the forefront of personalized medicine, driven by rapid advancements in laboratory genomics and molecular diagnostics.
FDA approved Darzalex Faspro (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide, and dexamethasone for the treatment of adult patients with newly diagnosed multiple ...
In today’s fast-moving world, health concerns are often pushed aside until symptoms become impossible to ignore. Unfortunately, when it comes to serious conditions like multiple myeloma, waiting can ...
The mother and daughter received identical diagnoses just over a year apart of multiple myeloma, a blood cancer that occurs ...
The International Myeloma Foundation (IMF) today welcomed Stephen L. Houff, MD, as the newest member of the IMF Board of ...
Johnson & Johnson’s Darzalex Faspro-based quadruplet regimen approved in US for newly diagnosed patients with multiple myeloma who are transplant ineligible: Horsham, Pennsylvan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results